103P - A prospective study on 70 patients with neo-adjuvant chemotherapy in locally advanced breast cancer (LABC)

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Locally Advanced
Presenter Mostafa Sumon
Citation Annals of Oncology (2016) 27 (suppl_9): ix30-ix34. 10.1093/annonc/mdw576
Authors M.A. Sumon1, A. Ahsan2, A.K. Uddin3
  • 1Clinical Oncology, kurmitola general hospital, 1212 - Dhaka/BD
  • 2Clinical Oncology, Shaheed Suhrawardy Medical College (ShSMC), Dhaka/BD
  • 3Radiation Oncology, United Hospital Ltd, Dhaka/BD



The purpose of our study is to assess the pathologic response of Neoadjuvant Chemotherapy (NACT) in locally advanced breast cancer (LABC) patients in a developing country like Bangladesh.


70 women were enrolled in the study during the period from Jan1997 to Dec 2015. All patients received six cycles NACT with FAC (5 Flurouracil 500mg/m2, Adriamycin 50mg/m2, Cylophosphamide500mg/m2 & docetaxel75mg/m2) followed by simple mastectomy & axillary dissection and radiotherapy. Surgery was undertaken between 4 to 6 weeks after the last chemotherapy and tumor specimens were examined for the presence of residual tumor. Complete absence of any malignant cell was considered as complete pathologic response (PCR). The last assessment of all the patients was done on April 2016.


Mean age was 46. Total 41(58.57%)patients were ER+&PR+,11Pts (15%) were triple negative . According to histopathology 32 Patients were well differentiated(Gr-1&Gr-2)and rest 38 patients(54.28%) were poorly differentiated. In these 70 patients 32 patients had no residual malignancy anywhere indicating that in this series around 45.71% had complete pathological response (PCR).


Pathological response to NACT is high in our population. The response is independent of age, grade& hormone status of tumor.This high rate could be due to the small deviations of our treatment schedule but perhaps more due to the biologically differenttumor behavior of this ethnically different group patients. A larger study may throw light on this issue.

Clinical trial indentification

Legal entity responsible for the study

Mostafa Aziz Sumon




All authors have declared no conflicts of interest.